
|Videos|July 21, 2017
Treatment of BRAF Mutated Non-Small Cell Lung Cancer
Treatment of BRAF Mutated Non-Small Cell Lung Cancer
Advertisement
- 67-year-old female, former smoker (30 pack-years, quit 10 years ago) presented to her pulmonologist with increased cough, dyspnea and hemoptysis.
- Past medical history of mild COPD.
- Patient swims three times a week and is continuing normal activities.
- ECOG PS was assessed as 1.
- CT scan of chest and abdomen show a lower right lobe lung nodule with several small liver lesions.
- PET/CT scan indicated lung cancer with liver metastases.
- Core needle biopsy was performed in the liver. Pathology report showed adenocarcinoma consistent with non-small cell lung cancer (NSCLC).
- Mutation testing showed aBRAF V600Emutation.
- PD-L1 status was negative.
- Patient was started on pemetrexed and carboplatin.
- After 3 of 6 planned cycles patient showed worsening signs of dyspnea with a weight loss of 10%.
- Repeat CT scan showed progression of primary lesion.
- Patient was started on dabrafenib + trametinib.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
5

































